New combination therapy for muscle-invasive bladder cancer receives expedited review
- FDA prioritizes review
- Padcev and Keytruda combination
- Targeting muscle-invasive bladder cancer
The U.S. Food and Drug Administration (FDA) has granted priority review status to Seattle BioMed's Padcev (enfortumab vedotin-ejfv) in combination with Keytruda (pembrolizumab) for treating muscle-invasive bladder cancer. This treatment is noteworthy as it can be used regardless of a patient's eligibility for cisplatin-based chemotherapy. This marks an important development in bladder cancer treatment options for patients facing this aggressive disease.
The priority review indicates that the FDA recognizes the urgent need for new therapies in this area. The application focuses on combining Padcev, an antibody-drug conjugate, with the immunotherapy Keytruda to potentially improve outcomes for muscle-invasive bladder cancer patients. This new approach aims to enhance tumor response and patient survival rates.
The priority review process accelerates the evaluation time, allowing for faster access to innovative treatments for patients. The FDA aims to improve healthcare outcomes by focusing on therapies that demonstrate significant promise in addressing unmet medical needs.
